A dominant role of thromboxane formation in secondary aggregation of platelets
- 1 November 1979
- journal article
- letter
- Published by Springer Nature in Nature
- Vol. 282 (5736) , 331-333
- https://doi.org/10.1038/282331a0
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- 9,11-Epoxyiminoprosta-5,13-dienoic acid is a thromboxane A2 antagonist in human plateletsNature, 1978
- Inhibition of human platelet thromboxane synthetase by 9,11-azoprosta-5,13-dienoic acid.Proceedings of the National Academy of Sciences, 1977
- Prostaglandin endoperoxides and thromboxane A2 can induce platelet aggregation in the absence of secretionNature, 1977
- Abnormal Platelet Function in Chediak‐Higashi SyndromeBritish Journal of Haematology, 1977
- Sodium Arachidonate Can Induce Platelet Shape Change and Aggregation Which Are Independent of the Release ReactionScience, 1976
- Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.Proceedings of the National Academy of Sciences, 1975
- Physiological role of an endoperoxide in human platelets: hemostatic defect due to platelet cyclo-oxygenase deficiency.Proceedings of the National Academy of Sciences, 1975
- Prostaglandin Endoperoxides. Novel Transformations of Arachidonic Acid in Human PlateletsProceedings of the National Academy of Sciences, 1974
- Formation of Prostaglandins during the Aggregation of Human Blood PlateletsJournal of Clinical Investigation, 1973
- Secretory mechanisms. Behaviour of adenine nucleotides during the platelet release reaction induced by adenosine diphosphate and adrenalineBiochemical Journal, 1972